

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 11/8/1981  
**Gender:** Female  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**NRAS Mutation Detection by Pyrosequencing**

ARUP test code 2003123

NRAS Mutation Detection, Pyrosequencing

Not Detected

A mutation in NRAS codons 12, 13 or 61 was not detected.

This result has been reviewed and approved by [REDACTED]

TEST INFORMATION: NRAS Mutation Detection Pyrosequencing

This assay is designed to detect mutations in codons 12, 13 and 61 of the NRAS gene which may indicate responsiveness to therapy that targets the MAP kinase pathway in melanoma as well as lack of response to EGFR inhibitors in other tumors, including colorectal cancer. Interpretation of NRAS test results depends on the tissue tested.

**MELANOMAS:** A mutation in the NRAS gene may indicate whether a tumor is likely to respond to therapy that targets the MAP kinase pathway.

**COLORECTAL:** A mutation in the NRAS gene may indicate lack of response to EGFR inhibitors.

**Methodology:** DNA is isolated from microdissected tumor tissue and amplified for codons 12, 13 and 61 of the NRAS gene. Mutation status is determined by pyrosequencing.

**Limitations:** Mutations in other locations within the NRAS gene or in other genes will not be detected.

**Limit of detection:** 10 percent mutant alleles.

**Clinical Disclaimer:** Results of this test must always be interpreted within the clinical context and other relevant data and should not be used alone for a diagnosis of malignancy. This test is not intended to detect minimal residual disease.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Block ID

1245

H=High, L=Low, \*=Abnormal, C=Critical

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
NRAS Mutation Detection, Pyrosequencing	21-318-108190	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Block ID	21-318-108190	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 21-318-108190  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 2 of 2 | Printed: 10/3/2022 1:48:37 PM  
4848